All the news Showing 10 of 18 articles from: Treatment in liver transplantedGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Surgeons plan to use hepatitis-infected hearts to slash wait for a transplant STAT / 15 May 2017 Curing hepatitis C will create transplant opportunities for patients with other illnesses EurekAlert (press release) / 04 May 2016 First Canadian Study Demonstrates Potential to Remove Patients from Active Liver Transplant List After Curing Hepatitis C Lawson Health Research Institute press release / 03 May 2016 U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease Gilead press release / 17 February 2016 U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Bristol-Myers Squibb press release / 08 February 2016 Olysio/Sovaldi yield high SVR post-liver transplant Healio / 08 February 2016 European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV Bristol-Myers Squibb press release / 01 February 2016 HCV at a Crossroads:The Pre- or Post-Transplant Treatment Debate Healio HCV Next / 15 June 2015 HIV did not affect HCC recurrence or survival after liver transplant Healio Hepatology / 04 March 2015 European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection Gilead press release / 17 January 2014 ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive